New Antifungal Agents and New Formulations Against Dermatophytes

The 2016 document reviews the treatment options for dermatophyte infections, noting that no new oral antifungals have been introduced since 2008, with terbinafine, itraconazole, and fluconazole remaining the standard. It highlights newer topical antifungals like efinaconazole, luliconazole, sertaconazole, and tavaborole, and discusses novel delivery systems for improved efficacy and compliance. The review covers the treatment of various tinea infections, emphasizing the importance of patient compliance and preventative measures. It also discusses the treatment of onychomycosis, with oral antifungals being the mainstay, and the potential of new formulations like ciclopirox 8% HPCH to increase cure rates. Combination therapies and prophylactic treatments are mentioned as ways to reduce recurrence. The document stresses the need for accurate diagnosis, patient education, and the treatment of family members in affected households to prevent reinfection.